The Daily News said the people are participating in the HIV Prevention Trials Network (HPTN 084) study being undertaken by Botswana-Harvard AIDS Institute Partnership.
Quoting study leader Alice Sehurutshi, the newspaper said the aim of the study is to evaluate the safety and efficiency of the injectable cabotegravir (CAB LA) over the Truvada pill.
“The HPTN 084 is comparing the efficacy and safety of CAB LA to daily oral Truvada (TDF and FCT) for PrEP in HIV uninfected women in sub-Saharan Africa,” Sehurutshi is quoted as saying.
While the injectable agent is given once every two weeks, the pill is taken every day.
Botswana is one of the countries with a high HIV and AIDS prevalence rates in Africa.